Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma

H Suzuki, SA Kumar, S Shuai, A Diaz-Navarro… - Nature, 2019 - nature.com
H Suzuki, SA Kumar, S Shuai, A Diaz-Navarro, A Gutierrez-Fernandez, P De Antonellis
Nature, 2019nature.com
In cancer, recurrent somatic single-nucleotide variants—which are rare in most paediatric
cancers—are confined largely to protein-coding genes,–. Here we report highly recurrent
hotspot mutations (r. 3A> G) of U1 spliceosomal small nuclear RNAs (snRNAs) in about 50%
of Sonic hedgehog (SHH) medulloblastomas. These mutations were not present across
other subgroups of medulloblastoma, and we identified these hotspot mutations in U1
snRNA in only< 0.1% of 2,442 cancers, across 36 other tumour types. The mutations occur …
Abstract
In cancer, recurrent somatic single-nucleotide variants—which are rare in most paediatric cancers—are confined largely to protein-coding genes, –. Here we report highly recurrent hotspot mutations (r.3A>G) of U1 spliceosomal small nuclear RNAs (snRNAs) in about 50% of Sonic hedgehog (SHH) medulloblastomas. These mutations were not present across other subgroups of medulloblastoma, and we identified these hotspot mutations in U1 snRNA in only <0.1% of 2,442 cancers, across 36 other tumour types. The mutations occur in 97% of adults (subtype SHHδ) and 25% of adolescents (subtype SHHα) with SHH medulloblastoma, but are largely absent from SHH medulloblastoma in infants. The U1 snRNA mutations occur in the 5′ splice-site binding region, and snRNA-mutant tumours have significantly disrupted RNA splicing and an excess of 5′ cryptic splicing events. Alternative splicing mediated by mutant U1 snRNA inactivates tumour-suppressor genes (PTCH1) and activates oncogenes (GLI2 and CCND2), and represents a target for therapy. These U1 snRNA mutations provide an example of highly recurrent and tissue-specific mutations of a non-protein-coding gene in cancer.
nature.com